National Cervical Cancer Prevention Program Strategic Plan 2012-2015

Objectives

Kenya’s National Cervical Cancer Prevention Strategic Plan for 2011–2015 provides a national framework to reduce cervical cancer incidence, prevalence, morbidity, mortality and associated costs, while improving patients’ quality of life and women’s access to prevention and treatment services.[1][2][3]Its vision is for Kenyan women to be free from cervical cancer, with a particular focus on women of reproductive age, women aged 25–49 or 25–50 years for screening, and women living with HIV.[2][4][5]

• Strengthen primary prevention by promoting education, safer sexual behaviour, condom use, tobacco-use prevention, male circumcision and human papillomavirus vaccination for girls aged 9–13 years, preferably before sexual debut.[6][7]
• Achieve at least 70% screening coverage among women in the age group with the greatest risk-benefit ratio, including through approaches suitable for rural and hard-to-reach populations.[6][4]
• Provide screening through visual inspection with acetic acid, visual inspection with Lugol’s iodine, conventional Pap smear cytology or human papillomavirus testing, according to national guidelines.[4]
• Ensure timely outpatient treatment of precancerous lesions through cryotherapy, loop electrosurgical excision procedure or cold knife conisation, preferably during a single visit to minimise revisits and loss to follow-up.[4][8][9]
• Expand diagnosis, treatment, referral and palliative care for invasive cancer, including quality-of-life support for patients and their families.[2][9][10]
• Create an enabling environment for the National Cervical Cancer Programme by strengthening leadership, coordination, partnerships, quality assurance, capacity building, information systems, referral arrangements and resource mobilisation.[2][11]

Implementation

The programme is designed for phased national implementation across all levels of the Kenyan health system, building on existing infrastructure, personnel and service entry points while expanding capacity according to available resources.[1][12]It integrates prevention and screening into routine maternal and child health, family planning, HIV comprehensive care, obstetric and gynaecology services, public and private facilities, outreach, in-reach and organised mass-screening activities.[4][8]Prevention and control are led through the Division of Reproductive Health, formerly within the Ministry of Public Health and Sanitation, while hospital-based management of overt cancer is the responsibility of the Ministry of Medical Services.[13]

• Deliver screening and immediate treatment through a single-visit see-and-treat model where trained personnel, equipment and supplies are available, and refer screen-positive clients from primary facilities to trained secondary or tertiary providers where this is not feasible.[7][4]
• Expand cryotherapy at lower service levels and model health centres, provide loop electrosurgical excision procedure at county hospitals and national referral sites, and decentralise biopsy, staging and histopathological diagnosis through specialist deployment.[14][9][15]
• Refer patients requiring radiotherapy to tertiary facilities while developing regional radiotherapy and cancer-treatment centres as services expand.[10][15]
• Strengthen palliative care by establishing or reinforcing hospices in each county, ensuring medicines and supplies, developing capacity at all service levels and supporting home-based care.[10]
• Train, supervise, certify and retain providers through pre-service curricula, competency-based in-service training, mentorship and workplace learning, with supervisors expected to retain trained staff in their units or service areas for at least two years.[2][10][16]
• Mobilise communities through Community Health Units, community health workers, schools, women’s and youth groups, religious and political leaders, professional bodies, workplaces, media, outreach camps and community champions, including treated clients.[6][17][16]
• Coordinate implementation through the Ministry of Health programme secretariat in the Division of Reproductive Health, provincial and district health management teams, reproductive health coordinators and the national Reproductive Tract Cancer technical working group.[10][18][19]
• Engage government sectors, development partners, private providers, faith-based and community-based organisations, universities, research institutions, professional associations and communities in service delivery, advocacy, research and resource mobilisation.[18][19]
• Use quarterly and annual coordination reviews, alongside mid-term and end-of-programme evaluations, under the Division of Reproductive Health and relevant health-sector coordinating committees.[18][19]
• Require facilities and practitioners providing screening to report to the Division of Reproductive Health, use standard facility registers and monthly summary tools, integrate indicators into routine health information systems, and link programme data to the national cancer registry.[10][17][18]
• Monitor coverage, service availability, trained workforce, visual inspection with acetic acid positivity, referrals, treatment uptake, complications and loss to follow-up, with an expected positivity range of 5–10% in general-population programmes and a target of at least 80% immediate cryotherapy among eligible women.[5][20][21]
• Mobilise start-up funding for training and equipment, supplement internal allocations with external funding, meet recurrent staff and supply costs through existing budgets and cost-recovery funds, and advocate for a dedicated cervical cancer budget line.[22]

Monitoring & Evaluation

The plan establishes a national monitoring and evaluation system to strengthen programme data capture, reporting, use, supervision, service quality and accountability across cervical cancer prevention, screening, treatment, referral and palliative care.[23][2][18]

• Establish a monitoring and evaluation framework, programme log frame, institutional framework and key performance indicators for the National Cervical Cancer Programme.[23][2]
• Integrate cervical screening and precancer-treatment indicators into routine health management information systems, annual operational plans and District Health Information System reporting.[10][18]
• Require public and private facilities and practitioners providing screening services to submit reports to the Division of Reproductive Health.[10][17]
• Maintain a Division of Reproductive Health database on programme roll-out, implementation and partner activities to support planning, scale-up, reporting and coordination.[10][19]
• Introduce facility-level tools including screening forms, daily registers, monthly summary tools, referral forms, data-use posters and supportive-supervision tools.[22][18]
• Link programme information with the national cancer registry, strengthen hospital and regional cancer registries, and improve the completeness, accuracy and timeliness of cancer data.[10][17][18]
• Conduct standard supervision at all Kenya Essential Package for Health levels to review staff performance, commodities, quality of care, coverage, record-keeping, reporting and client satisfaction.[10][18]
• Use surveys, observational visits, client interviews, baseline surveys, operational research and special studies where routine data are insufficient to assess coverage, quality, client satisfaction, community support and service cost-effectiveness.[22][18]
• Conduct quarterly and annual coordination reviews, alongside mid-term and end-of-programme evaluations, under the leadership of the Division of Reproductive Health and linked coordinating committees.[18][19]
• Evaluate progress periodically against the log frame, including an interim evaluation two years after programme initiation, and assess outcome and impact measures such as cervical cancer incidence and mortality.[18]
• Track screening coverage against the objective of reaching at least 70% of eligible women, using a five-year screening cycle for the general programme and more frequent screening for women living with HIV.[4][8]
• Monitor referral and treatment performance through measures of visual inspection with acetic acid positivity, referrals for suspected cancer or large lesions, immediate and eventual cryotherapy, treatment complications, follow-up losses and completion of loop electrosurgical excision procedures after referral.[20][21]
• Apply an expected visual inspection with acetic acid positivity range of 5% to 10% in general-population programmes and aim for at least 80% immediate cryotherapy among eligible women.[20]
• Measure service availability and workforce capacity through the number of visual inspection with acetic acid outlets, trained health workers, providers continuing visual inspection with acetic acid after one year, and referral or data-management plans approved by the Ministry of Health.[3][5]
• Use monthly summary forms and screening records for routine reporting, with selected results reported annually and disaggregated where specified by HIV status, visit type, site or provider.[20][21]
• Recognise facilities meeting defined performance levels through a standards-based management and recognition approach informed by baseline assessments.[21]

The source identifies earlier weaknesses in data capture, reporting, utilisation and monitoring and evaluation, but the supplied material does not provide a complete indicator matrix, detailed reporting timetable, evaluation protocol or fully specified accountability framework beyond the mechanisms described.[13][14][2]

Costing & Financing

Financing is framed around resource mobilisation, integration with existing services, government budget allocations, partner support and cost-effective delivery, but the supplied material provides no total programme cost, quantified financing gap, unit-cost schedule or monetary economic assumptions.[2][22][18]

• Maintain a Government budget line for equipment for cervical cancer treatment in the 2011/2012 financial year.[1]
• Allocate national-budget funds in the 2011/2012 financial year for procurement of cryotherapy equipment, with the intention of placing equipment in all model health centres.[4]
• Develop advocacy and resource-mobilisation strategies to secure national, provincial, district and facility budget allocations, supplemented by donor and external support.[2][22]
• Provide start-up financing for training and equipment, while meeting recurrent personnel and supply costs through existing budgets and cost-recovery funds.[22]
• Cost the programme for advocacy purposes and pursue a dedicated budget line for cervical cancer prevention and control.[22]
• Mobilise financial, human, material and technical resources under Ministry of Health leadership, informed by district staffing needs and facility-readiness assessments.[22][10]
• Prioritise investment in human papillomavirus vaccination, infrastructure, essential supplies, cryotherapy equipment, radiotherapy equipment and treatment facilities.[22][11]
• Integrate prevention and screening into existing maternal and child health, family planning, HIV and routine gynaecological services to share personnel, space, equipment, supplies and reporting systems.[4]
• Use low-cost screening and precancer treatment approaches, including cryotherapy, which is characterised as inexpensive and appropriate for low-resource settings.[6][9]
• Prefer outpatient treatment of precancerous lesions where appropriate, as inpatient approaches such as cone biopsy and hysterectomy are described as expensive and potentially prone to over-treatment.[8]
• Assess cost-effectiveness through special studies where routine programme data are inadequate.[18]

The anticipated economic benefits include reduced future demand for gynaecology cancer care, lower treatment costs and preserved productivity as healthier women continue contributing to society and the economy.[12][3]

No numeric programme budget, allocation amount, currency value, financing share, funding-gap estimate or quantified cost-benefit assumption is specified in the supplied sections.[22][11][24]